Sonoma Pharmaceuticals, Inc. (SNOA)

From the record

Sonoma Pharmaceuticals, Inc.'s filings since 2017 show 11 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2024-03-22); a warning not to rely on past financial statements (8-K item 4.02, the latest 2020-11-17); an auditor change (8-K item 4.01, 2 times, the latest 2021-07-20); a late-report notice (Form NT 10-K or NT 10-Q, 5 times, the latest 2022-06-29) (its current reports).

From the record

Sonoma Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $9 million in fiscal 2016 to $20 million in fiscal 2026, up 7.6% a year; it rose in 6 of 9 years; the deepest fall was 33% from fiscal 2019 to fiscal 2022; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2026-03-31, Sonoma Pharmaceuticals, Inc. lost about 103 cents for every dollar of shareholders' money, and gross profitability: its products earned about 53 cents per dollar of everything the company owns. Leverage: it owed about 78 cents per dollar of assets, and net share issuance: its share count grew 35.7% over the year (the filed statements).

From the record

Sonoma Pharmaceuticals, Inc.'s standing among 109 graded names in its industry family: revenue of $20 million in fiscal 2026 ranks in the bottom 28% by size; a net margin of -16.3% ranks in the top 45%; revenue growth of 13.7% a year over the last 3 filed years ranks in the bottom 50% (its annual reports).

From the record

Sonoma Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Trombly, Amy Moss (Chief Executive Officer, as filed), filing under that title since 2019-10-17, 7.1 years (top 34% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 7.1 years (top 25%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (bottom 25%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Sonoma Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $2 million against no long-term debt tagged leaves 17.2% of its assets as net cash, top 40% of its family; cash from operations less capital spending is -21.1% of revenue (bottom 40%); a gross margin of 38% (bottom 19%); research spending of 11.6% of revenue (top 47%) (its annual report).

From the record

Sonoma Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew 13.7% a year over the last three filed years against 7.6% over all 10, speeding up (top 17% of its family); the newest year grew 36.7% (top 18%); research spending grew 122.2% a year (top 1%); capital spending grew -10.6% a year (bottom 38%) (its annual reports). Sonoma Pharmaceuticals, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Sonoma Pharmaceuticals, Inc.'s newest year against its own record: revenue of $20 million in fiscal 2026 came in 31.7% above the $15 million its prior three years' pace pointed to (top 6% of its family); net income of $3 million against a prior three-year average of $4 million (top 43%); a net margin of -16.3% against -33.7% before (top 39%) (its annual reports).